Daratumumab for autoimmune diseases: a systematic review.
Marie-Therese HolzerNikolas RufferTobias B HuberIna KötterLennard OstendorfKrusche MartinPublished in: RMD open (2023)
Targeting CD38 via daratumumab is a new promising therapeutic option in therapy refractory autoimmune diseases. Efficacy as well as optimal therapeutic regimen and management or prevention of adverse events require further investigation. Therefore, systematic clinical trials of this therapeutic approach are needed.